اوسیمرتینیب (Persian Wikipedia)

Analysis of information sources in references of the Wikipedia article "اوسیمرتینیب" in Persian language version.

refsWebsite

Global rank Persian rank

7nih.gov

4^th place

5^th place

6doi.org

2^nd place

4web.archive.org

1^st place

1fda.gov

447^th place

382^nd place

1springer.com

274^th place

506^th place

1who.int

195^th place

129^th place

1cam.ac.uk

670^th place

767^th place

1sagepub.com

731^st place

681^st place

1worldcat.org

5^th place

12^th place

1medicines.org.uk

3,823^rd place

1,188^th place

1clinicaltrials.gov

5,225^th place

5,710^th place

1ahrq.gov

9,469^th place

low place

ahrq.gov

effectivehealthcare.ahrq.gov

"AHRQ Healthcare Horizon Scanning System – Potential High-Impact Interventions Report Priority Area 02: Cancer" (PDF). AHRQ. December 2015. Archived from the original (PDF) on 2017-04-30. Retrieved 2017-02-27.

cam.ac.uk

repository.cam.ac.uk

Tan CS, Gilligan D, Pacey S (September 2015). "Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer". The Lancet. Oncology. 16 (9): e447–e459. doi:10.1016/S1470-2045(15)00246-6. PMID 26370354.

clinicaltrials.gov

"Search of: Osimertinib - List Results - ClinicalTrials.gov". clinicaltrials.gov (به انگلیسی). Retrieved 2020-04-27.

doi.org

Ayeni D, Politi K, Goldberg SB (September 2015). "Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer". Clinical Cancer Research. 21 (17): 3818–20. doi:10.1158/1078-0432.CCR-15-1211. PMC 4720502. PMID 26169963.
Tan CS, Gilligan D, Pacey S (September 2015). "Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer". The Lancet. Oncology. 16 (9): e447–e459. doi:10.1016/S1470-2045(15)00246-6. PMID 26370354.
Xu M, Xie Y, Ni S, Liu H (May 2015). "The latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non-small cell lung cancer (NSCLC)". Annals of Translational Medicine. 3 (7): 96. doi:10.3978/j.issn.2305-5839.2015.03.60. PMC 4430733. PMID 26015938.
Patel H, Pawara R, Ansari A, Surana S (December 2017). "Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance". European Journal of Medicinal Chemistry. 142: 32–47. doi:10.1016/j.ejmech.2017.05.027. PMID 28526474.
Wang S, Song Y, Liu D (January 2017). "EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance". Cancer Letters. 385: 51–54. doi:10.1016/j.canlet.2016.11.008. PMID 27840244.
Bollinger, Meredith K; Agnew, Amanda S; Mascara, Gerard P (July 2018). "Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation". Journal of Oncology Pharmacy Practice (به انگلیسی). 24 (5): 379–388. doi:10.1177/1078155217712401. ISSN 1078-1552.

fda.gov

nctr-crs.fda.gov

"TAGRISSO FDA Label". nctr-crs.fda.gov. FDA. December 2019. Retrieved 2020-04-27.

medicines.org.uk

"UK label" (به انگلیسی). UK Electronic Medicines Compendium. 26 January 2017. Archived from the original on 27 February 2017. Retrieved 27 February 2017.

nih.gov

pubmed.ncbi.nlm.nih.gov

Ayeni D, Politi K, Goldberg SB (September 2015). "Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer". Clinical Cancer Research. 21 (17): 3818–20. doi:10.1158/1078-0432.CCR-15-1211. PMC 4720502. PMID 26169963.
Tan CS, Gilligan D, Pacey S (September 2015). "Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer". The Lancet. Oncology. 16 (9): e447–e459. doi:10.1016/S1470-2045(15)00246-6. PMID 26370354.
Xu M, Xie Y, Ni S, Liu H (May 2015). "The latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non-small cell lung cancer (NSCLC)". Annals of Translational Medicine. 3 (7): 96. doi:10.3978/j.issn.2305-5839.2015.03.60. PMC 4430733. PMID 26015938.
Patel H, Pawara R, Ansari A, Surana S (December 2017). "Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance". European Journal of Medicinal Chemistry. 142: 32–47. doi:10.1016/j.ejmech.2017.05.027. PMID 28526474.
Wang S, Song Y, Liu D (January 2017). "EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance". Cancer Letters. 385: 51–54. doi:10.1016/j.canlet.2016.11.008. PMID 27840244.

ncbi.nlm.nih.gov

Ayeni D, Politi K, Goldberg SB (September 2015). "Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer". Clinical Cancer Research. 21 (17): 3818–20. doi:10.1158/1078-0432.CCR-15-1211. PMC 4720502. PMID 26169963.
Xu M, Xie Y, Ni S, Liu H (May 2015). "The latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non-small cell lung cancer (NSCLC)". Annals of Translational Medicine. 3 (7): 96. doi:10.3978/j.issn.2305-5839.2015.03.60. PMC 4430733. PMID 26015938.

sagepub.com

journals.sagepub.com

Bollinger, Meredith K; Agnew, Amanda S; Mascara, Gerard P (July 2018). "Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation". Journal of Oncology Pharmacy Practice (به انگلیسی). 24 (5): 379–388. doi:10.1177/1078155217712401. ISSN 1078-1552.

springer.com

adisinsight.springer.com

"Osimertinib" (به انگلیسی). AdisInsight. Archived from the original on 23 August 2018. Retrieved 27 February 2017.

web.archive.org

"Osimertinib" (به انگلیسی). AdisInsight. Archived from the original on 23 August 2018. Retrieved 27 February 2017.
"Proposed INN: List 113" (PDF). International Nonproprietary Names for Pharmaceutical Substances (INN). 29 (2): 285. 2015. Archived (PDF) from the original on 28 April 2017. Retrieved 16 November 2015.
"UK label" (به انگلیسی). UK Electronic Medicines Compendium. 26 January 2017. Archived from the original on 27 February 2017. Retrieved 27 February 2017.
"AHRQ Healthcare Horizon Scanning System – Potential High-Impact Interventions Report Priority Area 02: Cancer" (PDF). AHRQ. December 2015. Archived from the original (PDF) on 2017-04-30. Retrieved 2017-02-27.

who.int

"Proposed INN: List 113" (PDF). International Nonproprietary Names for Pharmaceutical Substances (INN). 29 (2): 285. 2015. Archived (PDF) from the original on 28 April 2017. Retrieved 16 November 2015.

worldcat.org

Bollinger, Meredith K; Agnew, Amanda S; Mascara, Gerard P (July 2018). "Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation". Journal of Oncology Pharmacy Practice (به انگلیسی). 24 (5): 379–388. doi:10.1177/1078155217712401. ISSN 1078-1552.